Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Jacobien M. Kieffer, Tjeerd J. Postma, Lonneke van de Poll-Franse, Floortje Mols, Jan J. Heimans, Guido Cavaletti, Neil K. Aaronson, G. Cavaletti, D. R. Cornblath, I. S.J. Merkies, T. J. Postma, M. G. Valsecchi, S. Galimberti, E. Rossi, G. Cavaletti, B. Frigeni, F. Lanzani, L. Mattavelli, M. L. Piatti, P. Alberti & 31 others D. Binda, P. Bidoli, M. Cazzaniga, D. Cortinovis, J. Bruna, R. Velasco, A. A. Argyriou, H. P. Kalofonos, D. Psimaras, D. Ricard, A. Pace, E. Galiè, C. Briani, M. Lucchetta, M. Campagnolo, C. Dalla Torre, C. G. Faber, I. S.J. Merkies, E. K. Vanhoutte, M. Bakkers, B. Brouwer, M. Boogerd, R. I. Lalisang, W. Boogerd, D. Brandsma, L. Padua, G. Granata, R. Plasmati, A. Toscano, M. Russo, In Collaboration with the CI-PeriNomS Group

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). Methods: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified. Results: CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy. Conclusions: Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.

Original languageEnglish
Pages (from-to)2999-3010
Number of pages12
JournalQuality of Life Research
Volume26
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Peripheral Nervous System Diseases
Psychometrics
Statistical Factor Analysis
Drug Therapy
Checklist
Non-Small Cell Lung Carcinoma
Surveys and Questionnaires
Colorectal Neoplasms
Neoplasms

Keywords

  • Chemotherapy-induced peripheral neuropathy
  • Factor analysis
  • Measurement model
  • Symptom checklist

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Kieffer, J. M., Postma, T. J., van de Poll-Franse, L., Mols, F., Heimans, J. J., Cavaletti, G., ... In Collaboration with the CI-PeriNomS Group (2017). Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Quality of Life Research, 26(11), 2999-3010. https://doi.org/10.1007/s11136-017-1626-1

Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). / Kieffer, Jacobien M.; Postma, Tjeerd J.; van de Poll-Franse, Lonneke; Mols, Floortje; Heimans, Jan J.; Cavaletti, Guido; Aaronson, Neil K.; Cavaletti, G.; Cornblath, D. R.; Merkies, I. S.J.; Postma, T. J.; Valsecchi, M. G.; Galimberti, S.; Rossi, E.; Cavaletti, G.; Frigeni, B.; Lanzani, F.; Mattavelli, L.; Piatti, M. L.; Alberti, P.; Binda, D.; Bidoli, P.; Cazzaniga, M.; Cortinovis, D.; Bruna, J.; Velasco, R.; Argyriou, A. A.; Kalofonos, H. P.; Psimaras, D.; Ricard, D.; Pace, A.; Galiè, E.; Briani, C.; Lucchetta, M.; Campagnolo, M.; Torre, C. Dalla; Faber, C. G.; Merkies, I. S.J.; Vanhoutte, E. K.; Bakkers, M.; Brouwer, B.; Boogerd, M.; Lalisang, R. I.; Boogerd, W.; Brandsma, D.; Padua, L.; Granata, G.; Plasmati, R.; Toscano, A.; Russo, M.; In Collaboration with the CI-PeriNomS Group.

In: Quality of Life Research, Vol. 26, No. 11, 01.11.2017, p. 2999-3010.

Research output: Contribution to journalArticle

Kieffer, JM, Postma, TJ, van de Poll-Franse, L, Mols, F, Heimans, JJ, Cavaletti, G, Aaronson, NK, Cavaletti, G, Cornblath, DR, Merkies, ISJ, Postma, TJ, Valsecchi, MG, Galimberti, S, Rossi, E, Cavaletti, G, Frigeni, B, Lanzani, F, Mattavelli, L, Piatti, ML, Alberti, P, Binda, D, Bidoli, P, Cazzaniga, M, Cortinovis, D, Bruna, J, Velasco, R, Argyriou, AA, Kalofonos, HP, Psimaras, D, Ricard, D, Pace, A, Galiè, E, Briani, C, Lucchetta, M, Campagnolo, M, Torre, CD, Faber, CG, Merkies, ISJ, Vanhoutte, EK, Bakkers, M, Brouwer, B, Boogerd, M, Lalisang, RI, Boogerd, W, Brandsma, D, Padua, L, Granata, G, Plasmati, R, Toscano, A, Russo, M & In Collaboration with the CI-PeriNomS Group 2017, 'Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)', Quality of Life Research, vol. 26, no. 11, pp. 2999-3010. https://doi.org/10.1007/s11136-017-1626-1
Kieffer, Jacobien M. ; Postma, Tjeerd J. ; van de Poll-Franse, Lonneke ; Mols, Floortje ; Heimans, Jan J. ; Cavaletti, Guido ; Aaronson, Neil K. ; Cavaletti, G. ; Cornblath, D. R. ; Merkies, I. S.J. ; Postma, T. J. ; Valsecchi, M. G. ; Galimberti, S. ; Rossi, E. ; Cavaletti, G. ; Frigeni, B. ; Lanzani, F. ; Mattavelli, L. ; Piatti, M. L. ; Alberti, P. ; Binda, D. ; Bidoli, P. ; Cazzaniga, M. ; Cortinovis, D. ; Bruna, J. ; Velasco, R. ; Argyriou, A. A. ; Kalofonos, H. P. ; Psimaras, D. ; Ricard, D. ; Pace, A. ; Galiè, E. ; Briani, C. ; Lucchetta, M. ; Campagnolo, M. ; Torre, C. Dalla ; Faber, C. G. ; Merkies, I. S.J. ; Vanhoutte, E. K. ; Bakkers, M. ; Brouwer, B. ; Boogerd, M. ; Lalisang, R. I. ; Boogerd, W. ; Brandsma, D. ; Padua, L. ; Granata, G. ; Plasmati, R. ; Toscano, A. ; Russo, M. ; In Collaboration with the CI-PeriNomS Group. / Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). In: Quality of Life Research. 2017 ; Vol. 26, No. 11. pp. 2999-3010.
@article{10d82934e009478fa4340bdbfe6d14f4,
title = "Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)",
abstract = "Purpose: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). Methods: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified. Results: CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy. Conclusions: Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.",
keywords = "Chemotherapy-induced peripheral neuropathy, Factor analysis, Measurement model, Symptom checklist",
author = "Kieffer, {Jacobien M.} and Postma, {Tjeerd J.} and {van de Poll-Franse}, Lonneke and Floortje Mols and Heimans, {Jan J.} and Guido Cavaletti and Aaronson, {Neil K.} and G. Cavaletti and Cornblath, {D. R.} and Merkies, {I. S.J.} and Postma, {T. J.} and Valsecchi, {M. G.} and S. Galimberti and E. Rossi and G. Cavaletti and B. Frigeni and F. Lanzani and L. Mattavelli and Piatti, {M. L.} and P. Alberti and D. Binda and P. Bidoli and M. Cazzaniga and D. Cortinovis and J. Bruna and R. Velasco and Argyriou, {A. A.} and Kalofonos, {H. P.} and D. Psimaras and D. Ricard and A. Pace and E. Gali{\`e} and C. Briani and M. Lucchetta and M. Campagnolo and Torre, {C. Dalla} and Faber, {C. G.} and Merkies, {I. S.J.} and Vanhoutte, {E. K.} and M. Bakkers and B. Brouwer and M. Boogerd and Lalisang, {R. I.} and W. Boogerd and D. Brandsma and L. Padua and G. Granata and R. Plasmati and A. Toscano and M. Russo and {In Collaboration with the CI-PeriNomS Group}",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s11136-017-1626-1",
language = "English",
volume = "26",
pages = "2999--3010",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "11",

}

TY - JOUR

T1 - Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

AU - Kieffer, Jacobien M.

AU - Postma, Tjeerd J.

AU - van de Poll-Franse, Lonneke

AU - Mols, Floortje

AU - Heimans, Jan J.

AU - Cavaletti, Guido

AU - Aaronson, Neil K.

AU - Cavaletti, G.

AU - Cornblath, D. R.

AU - Merkies, I. S.J.

AU - Postma, T. J.

AU - Valsecchi, M. G.

AU - Galimberti, S.

AU - Rossi, E.

AU - Cavaletti, G.

AU - Frigeni, B.

AU - Lanzani, F.

AU - Mattavelli, L.

AU - Piatti, M. L.

AU - Alberti, P.

AU - Binda, D.

AU - Bidoli, P.

AU - Cazzaniga, M.

AU - Cortinovis, D.

AU - Bruna, J.

AU - Velasco, R.

AU - Argyriou, A. A.

AU - Kalofonos, H. P.

AU - Psimaras, D.

AU - Ricard, D.

AU - Pace, A.

AU - Galiè, E.

AU - Briani, C.

AU - Lucchetta, M.

AU - Campagnolo, M.

AU - Torre, C. Dalla

AU - Faber, C. G.

AU - Merkies, I. S.J.

AU - Vanhoutte, E. K.

AU - Bakkers, M.

AU - Brouwer, B.

AU - Boogerd, M.

AU - Lalisang, R. I.

AU - Boogerd, W.

AU - Brandsma, D.

AU - Padua, L.

AU - Granata, G.

AU - Plasmati, R.

AU - Toscano, A.

AU - Russo, M.

AU - In Collaboration with the CI-PeriNomS Group

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). Methods: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified. Results: CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy. Conclusions: Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.

AB - Purpose: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). Methods: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified. Results: CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy. Conclusions: Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.

KW - Chemotherapy-induced peripheral neuropathy

KW - Factor analysis

KW - Measurement model

KW - Symptom checklist

UR - http://www.scopus.com/inward/record.url?scp=85021136402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021136402&partnerID=8YFLogxK

U2 - 10.1007/s11136-017-1626-1

DO - 10.1007/s11136-017-1626-1

M3 - Article

VL - 26

SP - 2999

EP - 3010

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 11

ER -